US court upholds $142m Pfizer Neurontin verdict, reverses other rulings
This article was originally published in Scrip
A US appellate court upheld a $142 million verdict against Pfizer related to the past marketing of its epilepsy pill Neurontin. Perhaps more importantly, the major drug maker faces additional lawsuits from other insurers after rulings made by the court.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.